Coronavirus (COVID-19) News
Filter News
Found 2,648 articles
-
Scientists detail current evidence that Long COVID is caused by persistent SARS-CoV-2 viral reservoirs
9/7/2023
PolyBio Research Foundation is excited to announce a new publication in the journal Nature Immunology.
-
The vaccine maker reported new trial data confirming an 8.7 to 11-fold increase in neutralizing antibodies against circulating strains, including the highly watched BA.2.86, EG.5 and FL.1.5.1 variants.
-
EOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in Brazil
9/6/2023
EOM Pharmaceutical Holdings, Inc announced the results of its completed clinical trial in hospitalized COVID-19 patients with severe symptoms treated with its investigational immune-regulating drug product EOM613.
-
Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against BA.2.86
9/6/2023
Moderna, Inc. announced that clinical trial data from its research assay confirm its updated COVID-19 vaccine, which is pending approval by the U.S. Food and Drug Administration for the fall 2023 vaccination season, generates an 8.7-fold increase in neutralizing antibodies in humans against BA.2.86, a variant under monitoring.
-
The vaccine was effective against previous COVID-19 variants but lacked efficacy against new ones, the company announced Thursday, leaving the booster no commercially viable options.
-
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
8/30/2023
Pfizer Inc. and BioNTech SE announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended marketing authorization for the companies’ Omicron XBB.1.5-adapted monovalent COVID-19 vaccine administered as a single dose for individuals 5 years of age and older, regardless of prior COVID-19 vaccination history.
-
Clinical Labs' Quick Response to COVID-19 Helped Reduce Hospitalizations and Save Lives
8/29/2023
A new survey from the Association for Diagnostics & Laboratory Medicine found that clinical labs' robust, rapid response to the COVID-19 pandemic helped to contain the virus and save lives.
-
The biotech’s experimental vaccine has shown a neutralizing response to XBB sublineages of COVID-19, which currently dominate new cases in the U.S. and Europe.
-
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
8/21/2023
NanoViricides, Inc., a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported that the Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's broad-spectrum antiviral drug, is progressing successfully.
-
The companies contend that their updated COVID-19 vaccines for the fall vaccination season can elicit strong immune responses against the virus’ currently dominant and emerging subvariants.
-
Moderna Clinical Trial Data Confirm Its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants
8/17/2023
Moderna, Inc. announced that preliminary clinical trial data confirm its updated COVID-19 vaccine for the fall 2023 vaccination season showed a significant boost in neutralizing antibodies against EG.5 and FL.1.5.1 variants.
-
New research from The Jackson Laboratory: variable patient responses to SARS-CoV-2 infection are mimicked in genetically diverse mice
8/11/2023
Researchers at The Jackson Laboratory have created a panel of genetically diverse mice that accurately model the highly variable human response to SARS-CoV-2 infection.
-
The vaccine maker cut 25% of staff amid post-pandemic business challenges in May, but resurgent sales and an updated COVID-19 shot may prove a turning point.
-
Week in Review: Breakthrough Depression Drug, RSV and GLP-1 Lawsuits, and Earnings Season Shows C...
8/4/2023
A transformational moment in the treatment of depression, GSK takes first shot in a vaccine patent war with Pfizer, a Louisiana woman sues Novo Nordisk and Lilly, and companies face a steep COVID-19 cliff. -
Cue Health Awarded New $28 Million Federal Contract to Develop Flu A/B, RSV, COVID-19 Molecular Multiplex Test for Both Over-the-Counter and Point-of-Care Use
8/3/2023
Cue Health announced that it has been awarded a new approximately $28 million contract by the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to develop a Flu A/B, RSV, and COVID-19 molecular multiplex test for both over-the-counter and point-of-care use.
-
In its second-quarter earnings reported Tuesday, Pfizer announced total revenues declined 54% to $12.7 billion, primarily due to a plummet in Paxlovid and Comirnaty sales.
-
BD Receives 510(k) Clearance for COVID-19, Influenza A/B, RSV Molecular Combination Test
8/1/2023
BD, a leading global medical technology company, announced U.S. Food and Drug Administration 510 clearance for the BD Respiratory Viral Panel for BD MAX™ System, a single molecular diagnostic combination test that identifies and distinguishes SARS-CoV-2, influenza A, influenza B, and Respiratory Syncytial Virus in approximately two hours.
-
The infectious diseases market is expected to reach $150 billion in sales by 2029, with three pharma giants reaping most of its benefits, according to data analytics and consultancy GlobalData.
-
Biophytis has Requested a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19
7/20/2023
Biophytis SA announced that it has filed for a pre-submission meeting request with the Food and Drug Administration to discuss filing for Emergency Use Authorization in the United States for Sarconeos in the treatment of severe forms of COVID-19.
-
J&J, Merck and Pfizer are the subjects of a House Judiciary Committee investigation for their alleged participation in a government-sanctioned censorship campaign during the COVID-19 pandemic.